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While in immune competent populations, herpes zoster, also
called shingles, is most often seen in elderly persons, it is also
commonly reported among HIV-infected persons.1–5 After primary
infection with varicella zoster virus (VZV), usually during
childhood (chickenpox), the virus remains dormant in the sensoryociety for Infectious Diseases. Open access under CC BY-NC-SA license.
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immunocompromised and results in herpes zoster, a painful
vesicular rash that is self-limited.2,6,7 In HIV-infected patients,
herpes zoster can be more severe and prolonged, and may involve
the eye or central nervous system.6
While data are lacking for low-resource settings, statistics from
resource-rich environments suggest that while the lifetime risk of
a herpes zoster episode in the general population is between 25%
and 35%,8–10 the burden is substantially higher in HIV-infected
populations.3 Although some studies have found that the incidence
of herpes zoster has been decreasing since the scale-up of
antiretroviral therapy (ART), the risk of a herpes zoster episode
remains elevated in HIV-infected populations. In a recent study of
HIV-infected patients conducted in Germany, the incidence of
herpes zoster was 12/1000 person-years, while a cohort in the USA
experienced herpes zoster at a rate of 9/1000 person-years.11,12
These estimates are both substantially higher than the incidence
rate in the general population of resource-rich countries, which
ranges from 2/1000 person-years to approximately 5/1000 person-
years.10,13
To describe the characteristics of patients experiencing
episodes of herpes zoster after ART initiation, we assessed the
incidence of herpes zoster in a large cohort of ART-naı¨ve HIV-
infected patients initiating ART in Johannesburg, South Africa. We
further sought to identify characteristics that were associated with
an increased risk for a herpes zoster episode and the timing of
these episodes after initiation of ART.
2. Methods
2.1. Study site
The study was conducted at the Themba Lethu Clinic in
Johannesburg, South Africa. Themba Lethu is a large outpatient,
public sector HIV treatment clinic located within the Helen Joseph
Hospital that receives non-governmental organization (NGO)
support through the President’s Emergency Plan for AIDS Relief
(PEPFAR) program. ART at Themba Lethu has been provided in
accordance with South Africa’s national treatment guidelines since
it was ﬁrst made available in the public sector in 2004 and
currently follows the 2013 guidelines.14,15 Since 2004, approxi-
mately 30 000 patients have received HIV care at Themba Lethu
and over 21 000 patients have initiated ART.16
Prior to April 2010, patients were initiated on ART when they
reached a CD4 count of <200 cells/mm3 or if they experienced a
World Health Organization (WHO) stage IV condition. The primary
ART regimen was stavudine, lamivudine, and efavirenz, with
options to substitute zidovudine for stavudine, emtricitabine for
lamivudine, and nevirapine for efavirenz when indicated.14 After
April 2010, tenofovir was chosen to replace stavudine in ﬁrst-line
regimens and in August 2011, the ART eligibility threshold was
raised to a CD4 count of 350 cells/mm3.17,18
Patient details including demographic information, laboratory
test results, medications prescribed, clinical conditions, and other
clinical details are captured in an electronic medical record system
called TherapyEdge-HIVTM.16 Data are entered into the database at
the time of the clinical encounter by the treating clinician. Patients
are typically seen every month for the ﬁrst 6 months after ART
initiation and then every 2 months thereafter for either antiretro-
viral medication pick-ups and/or medical visits. The CD4 count is
assessed at ART initiation, 1 year after ART initiation, and yearly
thereafter, while viral load is assessed 4–6 months after ART
initiation, at 1 year, and then yearly thereafter.
While herpes zoster can be identiﬁed at regularly scheduled
visits, it is often diagnosed at an unscheduled medical visit or
retrospectively at the medical visit following the episode. Herpeszoster is diagnosed clinically, and treatment for the lesions is
provided with acyclovir and pain medication. Start and stop dates of
the episode are entered into TherapyEdge-HIVTM by the clinician.
2.2. Study population
We conducted a cohort analysis using data collected prospec-
tively as part of routine patient care. We included all ART-naı¨ve
adult patients (18 years old) who initiated any of the standard
public sector ﬁrst-line regimens listed above between April 2004
and August 2011 and had at least one visit after ART initiation at
the Themba Lethu Clinic. Loss to follow-up was deﬁned as 3
months late for a scheduled visit with no subsequent visit. Death
was ascertained through patient tracing. In addition, for patients
with a valid South African national identiﬁcation number (61%),
deaths were identiﬁed through linkage with the National Vital
Registration System.19 The last linkage occurred in September
2011.
2.3. Study variables
Patients were followed from the date of ART initiation until the
date of ﬁrst herpes zoster diagnosis, or death, transfer, loss to
follow-up, or dataset closure (September 6, 2012). Incident herpes
zoster was deﬁned as any herpes zoster episode occurring after the
date of ART initiation.
We deﬁned the baseline CD4 count to be the CD4 count
conducted closest to the date of ART initiation, from 6 months prior
to 7 days after ART initiation; this was categorized as <50 cells/
mm3, 50–99 cells/mm3, 100–199 cells/mm3, and 200 cells/mm3.
Classiﬁcation by WHO stage was done by the clinician. If the
clinician did not enter a classiﬁcation, the WHO stage was
determined according to the conditions present at ART initiation.
Body mass index (BMI) was categorized according to standard
categories (<18.5, 18.5–24.9, 25–29.9, 30 kg/m2). Before deﬁning
anemia, recorded hemoglobin values were adjusted downward by
0.65 g/dl to account for the elevation of Johannesburg.20 Anemia
was then deﬁned using WHO guidelines as severe, moderate, mild,
and none, which differ by sex (male: <8, 8–10, 11–12, 13 g/dl)
and pregnancy status (female, pregnant: <7, 7–9, 10, 11 g/dl;
female, not pregnant: <8, 8–10, 11, 12 g/dl).20 Finally, a prior
episode of herpes zoster was deﬁned as an episode that occurred
prior to, or was present at, ART initiation.
2.4. Statistical analysis
The demographic and baseline characteristics of all patients
included in the cohort are presented using frequencies for
categorical variables and medians with corresponding interquartile
ranges (IQR) for continuous variables. Incident herpes zoster rates
per 1000 person-years and the corresponding 95% conﬁdence
intervals (95% CI) and predictors of herpes zoster within 12 months
of ART initiation and herpes zoster ever on treatment are also
presented.
Fine and Gray’s method for competing risks regression was used
to estimate the subdistribution hazard ratios (sHR) of predictors of
herpes zoster for each model, accounting for the competing event
of mortality.21 Age, gender, and the baseline CD4 count were
included as covariates in each model. Other potential confounding
variables were included if they were plausible confounders based
on prior knowledge and were associated with herpes zoster (p <
0.2) in the crude analyses.
In order to determine whether an incident herpes zoster
diagnosis within 12 months of ART initiation had any impact on
short-term treatment outcomes, we matched each patient with a
herpes zoster diagnosis within 12 months of follow-up to eight
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(death and loss to follow-up) 12 months after the date of diagnosis.
Patients were matched on sex, age at ART initiation ( 5 years),
baseline CD4 count category, and time on treatment. For each
matched pair, the person-time accrued from the date of the incident
herpes zoster diagnosis or the equivalent duration of follow-up for
the matched subject who did not develop herpes zoster. We used a
log-binomial model to assess the risk of attrition by incident herpes
zoster status. Potential confounding variables that were plausible
confounders based on prior knowledge and were associated with
attrition (p < 0.2) in the univariate analyses were included in the
adjusted model.
3. Results
3.1. Demographic and clinical characteristics
Between April 2004 and August 2011, 15 025 patients initiated
a standard ﬁrst-line ART regimen at the Themba Lethu Clinic and
had at least one post-ART initiation follow-up visit. A further 2194
patients either did not initiate a standard ﬁrst-line regimen or did
not complete at least one follow-up visit and were excluded from
the analysis. Among included patients, 62.2% were female and the
median (IQR) age at ART initiation was 36.6 (31.4–43.1) years.
Many patients were severely immunosuppressed upon ARTTable 1
Patient demographics and clinical characteristics at treatment initiation and treatment
South Africa
Variable Exposure 
Total N 
Sex Male 
Female 
Age, years Median (IQR) n 
<30 
30–34.9 
35–39.9 
40–44.9 
45 
CD4 count, cells/mm3 Median (IQR) n 
Missing 
<50 
50–99 
100–199 
200 
WHO Stage I/II 
III/IV 
BMI Median (IQR) n 
Missing 
<18.5 
18.5–24.9 
25–29.9 
30 
Hemoglobin, g/dL Median (IQR) n 
Anemia Missing 
No anemia 
Mild anemia 
Moderate anemia 
Severe anemia 
Co-infected with tuberculosis Yes 
No 
Pregnant Yes 
No 
Prior episode of herpes zoster recorded Yes 
No 
Final treatment outcome Alive 
Dead 
Lost to follow-up 
Transferred out 
BMI, body mass index; IQR, interquartile range; WHO, World Health Organization.initiation, with the median (IQR) baseline CD4 count being 98
cells/mm3 (37–168 cells/mm3); almost a third of patients (29.6%)
had a baseline CD4 count <50 cells/mm3. Just under half of the
patients were moderately or severely anemic (48.2%) at ART
initiation, and tuberculosis co-infection was common (14.2%).
While patients who would go on to have an incident herpes zoster
episode had a slightly lower median baseline CD4 count at ART
initiation (77.5 cells/mm3 vs. 99 cells/mm3), other baseline
demographic and clinical characteristics were similar between
the groups (Table 1).
3.2. Incidence of herpes zoster
We identiﬁed 340 patients (2.3%) who had at least one episode
of incident herpes zoster recorded after ART initiation. Of those,
6.8% (n = 23) had a record of herpes zoster prior to, or present at,
ART initiation. The median (IQR) time to onset of herpes zoster
after ART initiation was 26.1 weeks (9.9–61.9 weeks) and the
majority of these cases (n = 243; 71.5%) occurred within the ﬁrst
year on treatment. Among the 243 patients diagnosed with herpes
zoster within 1 year of ART initiation, the median (IQR) time to
diagnosis was 16.0 weeks (6.3–29.6 weeks). This corresponded to
an overall incidence rate of 7.4/1000 person-years (95% CI: 6.6–8.2)
and a 1-year incidence rate of 18.1/1000 person-years (95% CI:
15.9–20.5). outcomes for patients initiating ART at the Themba Lethu Clinic in Johannesburg,
Incident herpes zoster
recorded
No incident herpes
zoster recorded
340 (100%) 14 685 (100%)
120 (35.3%) 5558 (37.8%)
220 (64.7%) 9127 (62.2%)
36.3 (31.7–44.3) 340 36.7 (31.4–43.1) 14 685
68 (20.0%) 2788 (19.0%)
79 (23.2%) 3385 (23.1%)
64 (18.8%) 3220 (21.9%)
54 (15.9%) 2350 (16.0%)
75 (22.1%) 2942 (20.0%)
77.5 (27–144) 330 99 (38–169) 14 243
10 (2.9%) 442 (3.0%)
128 (37.7%) 4320 (29.4%)
64 (18.8%) 2844 (19.4%)
108 (31.8%) 5111 (34.8%)
30 (8.8%) 1968 (13.4%)
197 (57.9%) 8535 (58.1%)
143 (42.1%) 6150 (41.9%)
21.5 (19.5–24.3) 314 21.5 (19.1–24.8) 13 307
27 (7.9%) 1437 (9.8%)
55 (16.2%) 2590 (17.6%)
193 (56.8%) 7515 (51.2%)
49 (14.4%) 2171 (14.8%)
16 (4.7%) 972 (6.6%)
11.1 (9.5–12.5) 321 10.9 (9.4–12.4) 13 716
19 (5.6%) 971 (6.6%)
83 (24.4%) 3396 (23.1%)
81 (23.8%) 3231 (22.0%)
132 (38.8%) 5700 (38.8%)
25 (7.4%) 1387 (9.5%)
44 (12.9%) 2093 (14.2%)
296 (87.1%) 12 592 (85.8%)
3 (0.9%) 147 (1.0%)
337 (99.1%) 14 538 (99.0%)
23 (6.8%) 626 (4.3%)
317 (93.2%) 14 059 (95.7%)
181 (53.2%) 7283 (49.6%)
34 (10.0%) 1528 (10.4%)
56 (16.5%) 3155 (21.5%)
69 (20.3%) 2719 (18.5%)
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Figure 1. Cumulative incidence curves for (a) herpes zoster within 12 months of
treatment initiation and (b) herpes zoster ever after ART initiation by baseline CD4
count among HIV-infected patients in Johannesburg, South Africa.
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76.8% (n = 261) had a CD4 count recorded after ART initiation at the
time of herpes zoster diagnosis (CD4 count date within 3 months
of the herpes zoster diagnosis date). The median (IQR) CD4 count at
diagnosis was 231 cells/mm3 (153–317 cells/mm3), and of the 76.5%
of patients with a viral load recorded within 3 months of the date of
herpes zoster diagnosis, 75.4% were virologically suppressed (viral
load <400 copies/ml).
3.3. Predictors of incident herpes zoster within 12 months and any
time after ART initiation
The CD4 count at ART initiation was a strong predictor of
incident herpes zoster diagnosed within 12 months (Figure 1).
Patients with a CD4 count <50 cells/mm3 had a 1-year incidence
rate of herpes zoster of 23.6/1000 person-years (95% CI: 19.2–
29.0), while patients with a CD4 count 200 cells/mm3 experi-
enced herpes zoster at half that rate (10.3/1000 person-years; 95%
CI: 6.6–16.2), corresponding to an increased risk of 2.02 for
patients with CD4 counts <50 cells/mm3 (95% CI: 1.31–3.22).
Those with a CD4 count between 50 and 99 cells/mm3 (sHR: 1.67,
95% CI: 1.04–2.74) were also at increased risk for a herpes zoster
diagnosis compared to patients with CD4 counts 200 cells/mm3
(Table 2).
When extending the timeframe for a herpes zoster diagnosis to
any time after ART initiation, a prior herpes zoster episode becamean important predictor of incident herpes zoster on ART. Patients
who had previously experienced herpes zoster were approxima-
tely 50% more likely to have an incident herpes zoster diagnosis
than patients who had never experienced herpes zoster (sHR: 1.53,
95% CI: 0.97–2.28). CD4 count remained a predictor of incident
herpes zoster diagnosis over this time period (Figure 1). Patients
with a CD4 count <50 cells/mm3 were about 70% more likely to
experience incident herpes zoster than patients with a CD4 count
200 cells/mm3 (sHR: 1.71, 95% CI: 1.21–2.47) (Table 2).
3.4. One-year treatment outcomes
Of the 243 patients who had a herpes zoster diagnosis recorded
within 1 year of ART initiation, 237 (97.5%) were matched to 1896
patients who did not experience herpes zoster within 1 year, for a
total of 2133 patients included in this sub-analysis. Among all 2133
patients, 295 (13.8%) died (4.5%) or were lost to follow up (9.3%).
Patients who experienced herpes zoster were less likely to die or
become lost to follow-up (9.7%) compared to non-herpes zoster
patients (14.4%) (aRR: 0.64, 95% CI: 0.42–0.99) (Table 3). As death
was similar across groups, the increase in attrition seen among
patients who did not experience a herpes zoster episode was
possibly due to increased monitoring of herpes zoster patients
resulting in less loss to follow-up among that group.
4. Discussion
In this cohort of newly initiating HIV-infected patients, the
overall burden of herpes zoster was low, with just 2% of patients
experiencing herpes zoster after ART initiation. While this is lower
than what has been found in other studies, ranging from 6.0% to
18.4%,11,12,22,23 the overall incidence rate of 7.4/1000 person-years
was still greater than that seen in 60-year-old patients in the USA
(5–6.5/1000 person-years) and similar to that seen in 70-year-old
Americans (8–11/1000 person-years).13,24 This was true despite
the fact that in our cohort the median age was <40 years. Further,
the 1-year incidence rate was high at 18.1/1000 person-years and
patients with low CD4 counts at ART initiation were consistently at
higher risk for a herpes zoster diagnosis than patients with CD4
counts 200 cells/mm3. Likewise, our ﬁnding that having had a
prior herpes zoster episode was potentially predictive of having
another herpes zoster episode after ART initiation is in line with the
results from other studies.4,25While in our study herpes zoster was
not shown to be associated with an increased risk of attrition,
clinicians should closely monitor patients at high risk for herpes
zoster in order to provide effective treatment as soon as possible
and thereby reduce the risk of complications associated with a
herpes zoster episode.
While a recent study showed that the herpes zoster vaccine,
Zostavax, was safe in HIV-infected patients with CD4 counts 200
cells/mm3,26 the majority of patients in our cohort initiated ART
with baseline CD4 counts below that level, and patients who went
on to develop incident herpes zoster initiated ART at CD4 counts
well below 100 cells/mm3 (median 77.5 cells/mm3). Patients also
developed herpes zoster quickly after ART initiation and most
experienced herpes zoster within 12 months of the date of
initiation. Therefore, if vaccination was possible in immunocom-
promised patients, it would be needed either at the time of
initiation or shortly after, before the immune system recovered
and CD4 counts increased. Due to the need to vaccinate patients
while still in an immunosuppressed state, further research is
needed to determine if a vaccine could be safe and effective in
immunocompromised patients such as these.
This study should be viewed in light of several limitations. First,
as patients may present with herpes zoster at a hospital or their
local primary care facility, we are likely underestimating the true
Table 2
Unadjusted and adjusted subdistribution hazard ratios for incident herpes zoster within 1 year and ever after ART initiation among HIV-infected patients at the Themba Lethu Clinic in Johannesburg, South Africa
Herpes zoster within 1 year of ART initiation Herpes zoster ever after ART initiation
Characteristic Herpes zoster/
person-years
Rate per 1000
person-years
Unadjusted
sHR (95% CI)
Adjusted
sHR (95% CI)
Herpes zoster/
person-years
Rate per 1000
person-years
Unadjusted
sHR (95% CI)
Adjusted
sHR (95% CI)
Sex
Male 93/5011.7 18.56 (18.05–19.08) 1.03 (0.79–1.33) 0.95 (0.72–1.24) 120/16610.1 7.22 (6.04–8.64) 0.92 (0.73–1.14) 0.90 (0.71–1.12)
Female 150/8448.2 17.76 (17.38–18.14) Reference Reference 220/29547.6 7.45 (6.52–8.50) Reference Reference
Age at initiation, years
<30 42/2548.3 16.48 (12.18–22.30) Reference Reference 68/8690.2 7.82 (6.17–9.92) Reference Reference
30–34 64/3125.2 20.48 (16.03–26.16) 1.24 (0.85–1.85) 1.24 (0.84–1.85) 79/11302.4 6.99 (5.61–8.71) 0.93 (0.67–1.29) 0.94 (0.68–1.30)
35–39 41/2970.3 13.80 (10.16–18.75) 0.83 (0.54–1.28) 0.84 (0.54–1.30) 64/10335.2 6.19 (4.85–7.91) 0.80 (0.57–1.12) 0.81 (0.57–1.14)
40–44 40/2145.3 18.65 (13.68–25.42) 1.12 (0.73–1.73) 1.15 (0.74–1.79) 54/7214.3 7.49 (5.73–9.77) 0.93 (0.65–1.33) 0.96 (0.67–1.38)
45 56/2671.0 20.97 (16.14–27.24) 1.26 (0.84–1.88) 1.32 (0.88–1.99) 75/8615.6 8.71 (6.94–10.92) 1.04 (0.75–1.45) 1.09 (0.78–1.53)
Baseline CD4+ count, cells/mm3
<50 90/3810.2 23.62 (19.21–29.04) 2.01 (1.31–3.19) 2.02 (1.31–3.22) 128/13 740.5 9.32 (7.83–11.08) 1.67 (1.18–2.41) 1.71 (1.21–2.47)
50–99 50/2624.5 19.05 (14.44–25.14) 1.69 (1.05–2.77) 1.67 (1.04–2.74) 64/9572.8 6.69 (5.23–8.54) 1.26 (0.85–1.89) 1.27 (0.86–1.89)
100–199 78/4785.5 16.30 (13.06–20.35) 1.46 (0.95–2.34) 1.46 (0.94–2.33) 108/16398.9 6.59 (5.45–7.95) 1.21 (0.85–1.75) 1.20 (0.84–1.74)
200 19/1843.2 10.31 (6.58–16.16) Reference Reference 30/5313.0 5.65 (3.95–8.08) Reference Reference
WHO stage
I/II 142/7971.2 17.81 (15.11–21.00) 1.00 (0.78–1.30) – 197/27168.4 7.25 (6.31–8.34) 0.99 (0.80–1.23) –
III/IV 101/5488.8 18.40 (15.14–22.36) Reference – 143/18989.3 7.53 (6.39–8.87) Reference –
BMI, kg/m2
<18.5 42/2253.9 18.63 (13.77–25.21) 0.93 (0.66–1.30) 0.87 (0.61–1.21) 55/7499.8 7.33 (5.63–9.55) 0.88 (0.65–1.17) –
18.5–24.9 139/7012.5 19.82 (16.79–23.41) Reference Reference 193/24676.4 7.82 (6.79–9.01) Reference –
25–29.9 34/2052.0 16.57 (11.84–23.19) 0.88 (0.60–1.26) 0.89 (0.60–1.28) 49/7178.1 6.83 (5.16–9.03) 0.91 (0.66–1.22) –
30 9/921.3 9.77 (5.08–18.77) 0.52 (0.25–0.96) 0.53 (0.25–0.99) 16/3170.4 5.05 (3.09–8.24) 0.66 (0.38–1.06) –
Anemia
None 53/3229.8 16.41 (12.54–21.48) Reference – 83/11240.5 7.38 (5.95–9.16) Reference –
Mild 57/3037.2 18.77 (14.48–24.33) 1.18 (0.83–1.69) – 81/10534.1 7.69 (6.18–9.56) 1.06 (0.79–1.42) –
Moderate 102/5144.2 19.83 (16.33–24.08) 1.22 (0.90–1.67) – 132/17565.1 7.51 (6.34–8.91) 1.00 (0.77–1.29) –
Severe 19/1155.5 16.44 (10.49–25.78) 0.95 (0.56–1.56) – 25/3813.0 6.56 (4.43–9.70) 0.80 (0.51–1.22) –
Tuberculosis
Yes 35/1895.0 18.47 (13.26–25.72) 1.01 (0.70–1.43) – 44/7180.8 6.13 (4.56–8.23) 0.86 (0.62–1.17) –
No 208/11564.9 17.99 (15.70 20.60) Reference – 296/38976.8 7.59 (6.78–8.51) Reference –
Prior episode of zoster
Yes 12/590.2 20.33 (11.55–35.80) 1.15 (0.61–1.96) – 23/2492.6 9.23 (6.13–13.89) 1.51 (0.96–2.25) 1.53 (0.97–2.28)
No 231/12869.8 17.95 (15.78–20.42) Reference – 317/43665.1 7.26 (6.50–8.10) Reference Reference
BMI, body mass index; CI, conﬁdence interval; sHR, subdistribution hazard ratio; WHO, World Health Organization.
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Table 3
Unadjusted and adjusted risk ratios for attrition among HIV-infected patients at the
Themba Lethu Clinic in Johannesburg, South Africa
Characteristic Attrition/n (%) Unadjusted RR
(95% CI)
Adjusted RR
(95% CI)
Herpes zoster within 1 year of ART initiation
Yes 23/237 (9.7%) 0.68 (0.45–1.01) 0.64 (0.42–0.99)
No 272/1896 (14.4%) Reference Reference
Sex
Male 136/819 (16.6%) 1.37 (1.11–1.70) 1.35 (1.05–1.73)
Female 159/1314 (12.1%) Reference Reference
Age at initiation, years
<30 48/374 (12.8%) Reference Reference
30–34 90/579 (15.5%) 1.21 (0.87–1.68) 1.04 (0.74–1.47)
35–39 38/353 (10.8%) 0.84 (0.56–1.25) 0.75 (0.49–1.14)
40–44 57/349 (16.3%) 1.27 (0.89–1.82) 1.02 (0.69–1.50)
45 62/478 (13.0%) 1.01 (0.71–1.44) 0.90 (0.62–1.30)
Baseline CD4 count, cells/mm3
<50 143/810 (17.7%) 1.26 (0.84–1.88) 0.94 (0.61–1.45)
50–99 54/450 (12.0%) 0.86 (0.55–1.34) 0.76 (0.47–1.22)
100–199 74/702 (10.5%) 0.75 (0.49–1.15) 0.70 (0.44–1.10)
200 24/171 (14.0%) Reference Reference
Baseline WHO stage
I/II 141/1218 (11.6%) Reference Reference
III/IV 154/915 (16.8%) 1.45 (1.18–1.80) 1.21 (0.96–1.53)
Baseline BMI, kg/m2
<18.5 80/405 (19.8%) 1.51 (1.18–1.94) 1.19 (0.92–1.54)
18.5–24.9 150/1150 (13.0%) Reference Reference
25–29.9 26/296 (8.8%) 0.67 (0.45–1.00) 0.80 (0.53–1.19)
30 13/121 (10.7%) 0.82 (0.48–1.41) 1.00 (0.58–1.73)
Anemia at ART initiation
None 54/515 (10.5%) Reference Reference
Mild 59/484 (12.2%) 1.16 (0.82–1.65) 1.08 (0.75–1.55)
Moderate 126/824 (15.3%) 1.46 (1.08–1.97) 1.35 (0.97–1.89)
Severe 45/209 (21.5%) 2.05 (1.43–2.95) 1.85 (1.24–2.77)
Tuberculosis co-infection
Yes 49/330 (14.9%) 1.09 (0.82–1.44) –
No 246/1803 (13.6%) Reference –
ART, antiretroviral therapy; BMI, body mass index; CI, conﬁdence interval; RR, risk
ratio; WHO, World Health Organization.
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While this would affect our incidence rates, our estimate of hazard
ratios should be unaffected because we believe we likely had near
perfect speciﬁcity of diagnosis of herpes zoster (very few false-
positives).27 Second, data on complications of herpes zoster were
unavailable, resulting in us being unable to quantify the number of
patients who experienced post-herpetic neuralgia and/or any
other complications of herpes zoster. Third, the last linkage to the
South African National Vital Registration System was done in
September 2011 and deaths occurring after then may not have
been captured in our records. Fourth, routine viral load testing at
baseline is not done in this cohort and thus, whilst patients were
generally at highest risk for a zoster diagnosis early after ART
initiation, we were unable to determine whether these episodes
were immune reconstitution inﬂammatory syndrome as we were
unable to assess an improvement in viral load from baseline.
Finally, data on patients who have yet to initiate ART are limited in
this cohort, rendering us unable to compare zoster incidence based
on ART exposure history.
Despite these limitations, our study also has many strengths.
Data can be entered into the electronic database retrospectively so
a patient can report an episode of herpes zoster to their clinician at
Themba Lethu and have the condition recorded even if they were
not diagnosed on site. Similarly, due to the retrospective nature of
diagnoses in the database, we were able to control for the effect of
prior herpes zoster episodes, even those that occurred before a
patient initiated ART, on the incidence of herpes zoster after
initiation.
In conclusion, Herpes zoster is a painful condition that can be
quite debilitating. As HIV-infected patients have been found to beat the same risk of developing herpes zoster as uninfected elderly
adults, further research is needed to determine the safety and
efﬁcacy of the herpes zoster vaccine in such patients in order to
reduce the morbidity associated with herpes zoster after ART
initiation.
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